The Key Role of Nucleic Acid Vaccines for One Health

Fomsgaard, Anders; Liu, Margaret A.

doi:10.3390/v13020258

Cited by 26 publications

(15 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The DNA vaccines can be designed and produced quickly once the genetic sequence is known and adapted rapidly to new emerging viral variants of concern. Clinically, the DNA vaccine modality is generally regarded as safe and is immunogenic in many different mammalian species including man 2 , 3 . Inducing both broad antibody and cellular immune responses, DNA vaccines have the potential to reduce both infection and disease.…”

Section: Introductionmentioning

confidence: 99%

Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2

et al. 2021

Self Cite

View full text Add to dashboard Cite

New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The DNA vaccine induced spike-specific binding IgG and neutralizing antibodies in mice, rabbits, and rhesus macaques together with robust Th1 dominant cellular responses in small animals. Intradermal and intramuscular needle-free administration of the DNA vaccine yielded comparable immune responses. In a vaccination-challenge study of rhesus macaques, the vaccine demonstrated protection from viral replication in the lungs following intranasal and intratracheal inoculation with SARS-CoV-2. In conclusion, the candidate plasmid DNA vaccine encoding the SARS-CoV-2 spike protein is immunogenic in different models and confers protection against lung infection in nonhuman primates. Further evaluation of this DNA vaccine candidate in clinical trials is warranted.

show abstract

Section: Introductionmentioning

confidence: 99%

Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…DNA immunization has the advantage of priming the immune system in the presence of maternal antibodies. However, DNA induced immune response will mostly cell mediated (through CD8 T cell response) with weak humoral immune response (Fomsgaard and Liu, 2021). In contrast to DNA vaccine, in which the immune response closely resembles natural infection, the immune Similarly, earlier studies also showed active stimulation of CMI following rgD and gD plasmid DNA immunization (Ruitenberg et al, 2000;Zhang et al, 2000).…”

Section: Rgb Immunization Restricts Virus Replication and Shedding In Immunized Micementioning

confidence: 99%

Recombinant Glycoprotein B of Equine herpesvirus Type 1 Elicits Protective Immune Response against Challenge in BALB/c Mouse Model

Joshi

Gupta

Pavulraj

et al. 2021

IJAR

View full text Add to dashboard Cite

Background: Equine herpesvirus type 1 (EHV-1) is the most important viral pathogen of equines, causing respiratory illness, abortion, neonatal foal mortality and neurologic disorders. Large numbers of commercial EHV-1 vaccines are available to protect equines from the disease, but they provide only partial protection. Despite immunization with inactivated and modified live virus vaccine, mares show abortions. Present study was aimed to investigate the immunogenicity and protective efficacy of EHV-1 recombinant glycoprotein B (rgB) and gB expressing plasmid DNA against EHV-1 infection in BALB/c mice model.Methods: About 3-4 weeks old 225 female BALB/c mice were selected for the comparative study of immunization followed by challenged with EHV-1/India/Tohana/96-2 strain virus in 5 different groups of 45 animals each.Result: Following immunization, rgB vaccinated mice showed optimal stimulation of EHV-1 gB specific cell mediated and humoral mediated immunity (HMI and CMI). The gB expressing plasmid DNA vaccinated mice developed only CMI while inactivated whole virus vaccinated mice had only HMI. Upon EHV-1 challenge, all infected mice displayed variable levels of clinical signs with changes in body weight, however, vaccinated mice showed very rapid recovery with optimal protection. Positive control group mice showed severe pulmonary lesions along with persistence virus infection till 5 days post challenge (dpc) whereas vaccinated mice had less pulmonary lesion only up to 3dpc. Minimal lung lesions and early virus clearance was observed in the rgB immunized mice in comparison to the gB plasmid DNA and inactivated EHV-1 vaccine immunized mice. It has been concluded that immunization with rgB elicits optimum protective immune response against EHV-1 infection in mice model. The rgB could be a potential vaccine candidate against EHV-1 infection in equine in the future.

show abstract

“…With regards to the search on DNA vaccines, most of the articles retrieved were on vaccines that were experimentally developed. Although many DNA vaccine candidates have been evaluated with promising results in various animal species, it has been estimated, by a recent review, that only five DNA vaccines have been approved and licensed for veterinary use [130]. These include:…”

Section: Summary Of Evidencementioning

confidence: 99%

“…Conversely, no DNA vaccines have been licensed for human use to date [33,130]. DNA vaccination involves immunization with a plasmid encoding a gene of the pathogen.…”

mentioning

confidence: 99%

Thermostable Vaccines in Veterinary Medicine: State of the Art and Opportunities to Be Seized

et al. 2022

View full text Add to dashboard Cite

The COVID-19 pandemic has highlighted the weakness of the vaccine supply chain, and the lack of thermostable formulations is one of its major limitations. This study presents evidence from peer-reviewed literature on the development of thermostable vaccines for veterinary use. A systematic review and meta-analysis were performed to evaluate the immunogenicity and/or the efficacy/effectiveness of thermostable vaccines against infectious diseases. The selected studies (n = 78) assessed the vaccine’s heat stability under different temperature conditions and over different periods. Only one study assessed the exposure of the vaccine to freezing temperatures. Two field studies provided robust evidence on the immunogenicity of commercial vaccines stored at temperatures far in excess of the manufacturer’s recommended cold-chain conditions. The drying process was the most-used method to improve the vaccine’s thermostability, along with the use of different stabilizers. The pooled vaccine efficacy was estimated to be high (VE = 69%), highlighting the importance of vaccination in reducing the economic losses due to the disease impact. These findings provide evidence on the needs and benefits of developing a portfolio of heat- and freeze-stable veterinary vaccines to unleash the true potential of immunization as an essential component of improved animal health and welfare, reduce the burden of certain zoonotic events and thus contribute to economic resilience worldwide.

show abstract

The Key Role of Nucleic Acid Vaccines for One Health

Cited by 26 publications

References 97 publications

Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2

Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2

Recombinant Glycoprotein B of Equine herpesvirus Type 1 Elicits Protective Immune Response against Challenge in BALB/c Mouse Model

Thermostable Vaccines in Veterinary Medicine: State of the Art and Opportunities to Be Seized

Contact Info

Product

Resources

About